Possible infection with live vaccines, zidovudine, zalccitabine, May alter action of oral anticogulants and phenytionFluorouracil may increase potential for neurotoxicity.Modulates metabolism any cytotoxicity of cytrabine.May precipitate didanosine or stavudine- induced pancreatitis,
hepatoxicity or neuropathy Impairs immune response to vaccines,

Possible infection with live vaccines, zidovudine, zalccitabine,

May alter action of oral anticogulants and phenytion

Fluorouracil may increase potential for neurotoxicity.

Modulates metabolism any cytotoxicity of cytrabine.

May precipitate didanosine or stavudine- induced pancreatitis,
hepatoxicity or neuropathy

Malignancies

GI disturbances, renal impairment, pulmonary edema,

Dermatogical reactions, headache, dizziness

Disorientation, drowsiness, hallucinations, convulsions,

Alopecia, bone marrow suppressionGI disturbances, renal impairment, pulmonary edema,

Dermatogical reactions, headache, dizziness

Disorientation, drowsiness, hallucinations, convulsions,

Alopecia, bone marrow suppression

Severe bone-marrow suppression, severe anemia,

WBC count < 3000/mm3 or platelet count < 100,000/mm3

Pregnancy, lactation
Hypersensitivity

Special instructions-
Regular monitoring of uric acid concentration, blood counts, renal
and hepatic function is  recommended

Prior irradiation therapy
Elderly, Avoid use of vaccines

Indication-
Malingancies

Dosage-
Adult- treatment of chronic myeloid leukamia-
20-30 mg/kg/day in single doses

Treatment of solid tumors-
Single doses of 80mg/kg/day every 3rd day .
If used in radiotherapy , treatment should be started 7 days before initiation of therapy

Single sickness disease-
Adult- 15mg/kg/day every 12 week  according to response and blood counts

Max- 35mg/kg/day daily
child- 1-18 yr 10-20mg/kg /day. Increased by 5mg/kg/day every 12 weeks according
to response and blood counts

Essential thrombocytomia-
  15mg/kg/day . Adjust subsequent based on platelet counts

Use contraindicated . Observe caution if use required